Neuropeptides in depression: Role of VGF

Behavioural Brain Research

Volumn 197, Issue 2, 2009, Pages 262-278

  Thakker Varia, Smita ^a   Alder, Janet ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Depression; Hippocampus; Mood disorder; Neurogenesis; Neuropeptide; Neurotrophin; Synaptic plasticity; VGF

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; NEUROPEPTIDE; NEUROPEPTIDE VGF; UNCLASSIFIED DRUG;

DEPRESSION; DRUG EFFECT; HIPPOCAMPUS; HUMAN; MOLECULAR DYNAMICS; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; NEUROGENESIS; NEURONAL PLASTICITY; NEURONS; NEUROPEPTIDES; UP-REGULATION;

EID: 58149512288     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.10.006     Document Type: Review

References (344)

1. Ballas C., Staab J.P., and Evans D.L. Strategies for treatment-resistant depression. Psychopharmacol Bull 36 4 (2002) 39-62
2. Adell A., et al. Strategies for producing faster acting antidepressants. Drug Discov Today 10 8 (2005) 578-585
3. Videbech P., and Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 161 11 (2004) 1957-1966
4. Neumeister A., et al. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry 57 8 (2005) 935-937
5. Castren E. Is mood chemistry?. Nat Rev Neurosci 6 3 (2005) 241-246
6. Dranovsky A., and Hen R. Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry 59 12 (2006) 1136-1143
7. Warner-Schmidt J.L., and Duman R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16 3 (2006) 239-249
8. Campbell S., and Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 29 6 (2004) 417-426
9. MacQueen G.M., et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 100 3 (2003) 1387-1392
10. Stockmeier C.A., et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 56 9 (2004) 640-650
11. Mayberg H.S., et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48 8 (2000) 830-843
12. Kennedy S.H., et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 158 6 (2001) 899-905
13. Hasler G., et al. Discovering endophenotypes for major depression. Neuropsychopharmacology 29 10 (2004) 1765-1781
14. Pittenger C., and Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33 1 (2008) 88-109
15. Azmitia E.C., et al. Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 14 1 (1996) 35-46
16. Patel T.D., Azmitia E.C., and Zhou F.C. Increased 5-HT1A receptor immunoreactivity in the rat hippocampus following 5,7-dihydroxytryptamine lesions in the cingulum bundle and fimbria-fornix. Behav Brain Res 73 1-2 (1996) 319-323
17. Sapolsky R.M., and Glucocorticoids. hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 57 10 (2000) 925-935
18. McEwen B.S. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 54 5 Suppl. 1 (2005) 20-23
19. Duman R.S., Heninger G.R., and Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 54 7 (1997) 597-606
20. Murer M.G., Yan Q., and Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63 1 (2001) 71-124
21. Masana Y., et al. Localization of trkB mRNA in postnatal brain development. J Neurosci Res 35 5 (1993) 468-479
22. Nibuya M., Nestler E.J., and Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16 7 (1996) 2365-2372
23. Conti A.C., et al. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 22 8 (2002) 3262-3268
24. Manji H.K., and Duman R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 35 2 (2001) 5-49
25. Martinowich K., Manji H., and Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 10 9 (2007) 1089-1093
26. Schmidt H.D., and Duman R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 18 5-6 (2007) 391-418
27. Altar C.A. Neurotrophins and depression. Trends Pharmacol Sci 20 2 (1999) 59-61
28. Post R.M. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res 41 12 (2007) 979-990
29. Kozisek M.E., Middlemas D., and Bylund D.B. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol Ther 117 1 (2008) 30-51
30. Cunha A.B., et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 398 3 (2006) 215-219
31. Palomino A., et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 86 1-3 (2006) 321-322
32. Karege F., et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 109 2 (2002) 143-148
33. Shimizu E., et al. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 351 2 (2003) 111-114
34. Aydemir O., Deveci A., and Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 29 2 (2005) 261-265
35. Gervasoni N., et al. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 51 4 (2005) 234-238
36. Gonul A.S., et al. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 255 6 (2005) 381-386
37. Marano C.M., et al. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry 68 4 (2007) 512-517
38. Bocchio-Chiavetto L., et al. Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. Eur Neuropsychopharmacol 16 8 (2006) 620-624
39. Karege F., et al. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 136 1-2 (2005) 29-37
40. Torrey E.F., et al. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 57 3 (2005) 252-260
41. Dwivedi Y., et al. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60 8 (2003) 804-815
42. Chen B., et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 50 4 (2001) 260-265
43. Gronli J., et al. Chronic mild stress inhibits BDNF protein expression and CREB activation in the dentate gyrus but not in the hippocampus proper. Pharmacol Biochem Behav 85 4 (2006) 842-849
44. Murakami S., et al. Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustly. Neurosci Res 53 2 (2005) 129-139
45. Smith M.A., et al. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 15 3 Pt 1 (1995) 1768-1777
46. Chen A.C., et al. ECS-Induced mossy fiber sprouting and BDNF expression are attenuated by ketamine pretreatment. J Ect 17 1 (2001) 27-32
47. Altar C.A., et al. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 54 7 (2003) 703-709
48. Nibuya M., Morinobu S., and Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15 11 (1995) 7539-7547
49. Russo-Neustadt A.A., et al. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology 29 12 (2004) 2189-2199
50. Zetterstrom T.S., Pei Q., and Grahame-Smith D.G. Repeated electroconvulsive shock extends the duration of enhanced gene expression for BDNF in rat brain compared with a single administration. Brain Res Mol Brain Res 57 1 (1998) 106-110
51. Rantamaki T., et al. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology 32 10 (2007) 2152-2162
52. Groves J.O. Is it time to reassess the BDNF hypothesis of depression?. Mol Psychiatry 12 12 (2007) 1079-1088
53. Coppell A.L., Pei Q., and Zetterstrom T.S. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 44 7 (2003) 903-910
54. Altieri M., et al. Expression analysis of brain-derived neurotrophic factor (BDNF) mRNA isoforms after chronic and acute antidepressant treatment. Brain Res 1000 1-2 (2004) 148-155
55. Dias B.G., et al. Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 45 4 (2003) 553-563
56. Jacobsen J.P., and Mork A. The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 1024 1-2 (2004) 183-192
57. Balu D.T., et al. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res 1211 (2008) 37-43
58. Martinowich K., and Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 33 1 (2008) 73-83
59. Vaidya V.A., et al. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 17 8 (1997) 2785-2795
60. Zetterstrom T.S., et al. Manipulations of brain 5-HT levels affect gene expression for BDNF in rat brain. Neuropharmacology 38 7 (1999) 1063-1073
61. de Foubert G., O'Neill M.J., and Zetterstrom T.S. Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression. Neuroscience 147 3 (2007) 778-785
62. Siuciak J.A., et al. BDNF induction of tryptophan hydroxylase mRNA levels in the rat brain. J Neurosci Res 52 2 (1998) 149-158
63. Galter D., et al. Differential regulation of distinct phenotypic features of serotonergic neurons by bone morphogenetic proteins. Eur J Neurosci 11 7 (1999) 2444-2452
64. Rumajogee P., et al. Up-regulation of the neuronal serotoninergic phenotype in vitro: BDNF and cAMP share Trk B-dependent mechanisms. J Neurochem 83 6 (2002) 1525-1528
65. Rumajogee P., et al. Rapid up-regulation of the neuronal serotoninergic phenotype by brain-derived neurotrophic factor and cyclic adenosine monophosphate: relations with raphe astrocytes. J Neurosci Res 81 4 (2005) 481-487
66. Szapacs M.E., et al. Exploring the relationship between serotonin and brain-derived neurotrophic factor: analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression. J Neurosci Methods 140 1-2 (2004) 81-92
67. Daws L.C., et al. Serotonin transporter function, but not expression, is dependent on brain-derived neurotrophic factor (BDNF): in vivo studies in BDNF-deficient mice. J Neurochem 101 3 (2007) 641-651
68. Ren-Patterson R.F., et al. Loss of brain-derived neurotrophic factor gene allele exacerbates brain monoamine deficiencies and increases stress abnormalities of serotonin transporter knockout mice. J Neurosci Res 79 6 (2005) 756-771
69. Benmansour S., et al. Influence of brain-derived neurotrophic factor (BDNF) on serotonin neurotransmission in the hippocampus of adult rodents. Eur J Pharmacol 587 1-3 (2008) 90-98
70. Guiard B.P., et al. Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype. Int J Neuropsychopharmacol 11 1 (2008) 79-92
71. Chan J.P., et al. Examination of behavioral deficits triggered by targeting Bdnf in fetal or postnatal brains of mice. Neuroscience 142 1 (2006) 49-58
72. Cotman C.W., Berchtold N.C., and Christie L.A. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci 30 9 (2007) 464-472
73. Cotman C.W., and Berchtold N.C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 25 6 (2002) 295-301
74. Russo-Neustadt A., Beard R.C., Cotman C.W., and Exercise. antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 21 5 (1999) 679-682
75. Berchtold N.C., et al. Exercise primes a molecular memory for brain-derived neurotrophic factor protein induction in the rat hippocampus. Neuroscience 133 3 (2005) 853-861
76. Adlard P.A., et al. The timecourse of induction of brain-derived neurotrophic factor mRNA and protein in the rat hippocampus following voluntary exercise. Neurosci Lett 363 1 (2004) 43-48
77. Zheng H., et al. Beneficial effects of exercise and its molecular mechanisms on depression in rats. Behav Brain Res 168 1 (2006) 47-55
78. Russo-Neustadt A., et al. Physical activity-antidepressant treatment combination: impact on brain-derived neurotrophic factor and behavior in an animal model. Behav Brain Res 120 1 (2001) 87-95
79. Russo-Neustadt A.A., et al. Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus. Neuroscience 101 2 (2000) 305-312
80. Engesser-Cesar C., Anderson A.J., and Cotman C.W. Wheel running and fluoxetine antidepressant treatment have differential effects in the hippocampus and the spinal cord. Neuroscience 144 3 (2007) 1033-1044
81. Egan M.F., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112 2 (2003) 257-269
82. Frodl T., et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry 64 4 (2007) 410-416
83. Hwang J.P., et al. The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression. Neurobiol Aging 27 12 (2006) 1834-1837
84. Strauss J., et al. Brain-derived neurotrophic factor variants are associated with childhood-onset mood disorder: confirmation in a Hungarian sample. Mol Psychiatry 10 9 (2005) 861-867
85. Kaufman J., et al. Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry 59 8 (2006) 673-680
86. Craddock N., and Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet 14 6 (2006) 660-668
87. Farmer A., Elkin A., and McGuffin P. The genetics of bipolar affective disorder. Curr Opin Psychiatry 20 1 (2007) 8-12
88. Jiang X., et al. BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology 30 7 (2005) 1353-1361
89. Agartz I., et al. BDNF gene variants and brain morphology in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 141 5 (2006) 513-523
90. Ho B.C., et al. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 63 7 (2006) 731-740
91. Jonsson E.G., et al. Brain-derived neurotrophic factor gene (BDNF) variants and schizophrenia: an association study. Prog Neuropsychopharmacol Biol Psychiatry 30 5 (2006) 924-933
92. Qian L., et al. Brain-derived neurotrophic factor and risk of schizophrenia: an association study and meta-analysis. Biochem Biophys Res Commun 353 3 (2007) 738-743
93. Tan Y.L., et al. Effect of BDNF Val66MMet genotype on episodic memory in schizophrenia. Schizophr Res 77 2 (2005) 355-356
94. Iga J., et al. The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with psychotic feature and suicidal behavior in Japanese major depressive patients. Am J Med Genet B Neuropsychiatr Genet 144B 8 (2007) 1003-1006
95. Neves-Pereira M., et al. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet 71 3 (2002) 651-655
96. Sklar P., et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Mol Psychiatry 7 6 (2002) 579-593
97. Sen S., et al. A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 28 2 (2003) 397-401
98. Lang U.E., et al. Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berl) 180 1 (2005) 95-99
99. Hong C.J., et al. Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology 48 4 (2003) 186-189
100. Tsai S.J., et al. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 123B 1 (2003) 19-22
101. Choi M.J., et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 1118 1 (2006) 176-182
102. Surtees P.G., et al. No association between the BDNF Val66Met polymorphism and mood status in a non-clinical community sample of 7389 older adults. J Psychiatr Res 41 5 (2007) 404-409
103. Willis-Owen S.A., et al. The Val66Met coding variant of the brain-derived neurotrophic factor (BDNF) gene does not contribute toward variation in the personality trait neuroticism. Biol Psychiatry 58 9 (2005) 738-742
104. Chen Z.Y., et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 314 5796 (2006) 140-143
105. Siuciak J.A., et al. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 56 1 (1997) 131-137
106. Shirayama Y., et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 22 8 (2002) 3251-3261
107. Hoshaw B.A., Malberg J.E., and Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 1037 1-2 (2005) 204-208
108. MacQueen G.M., et al. Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression. Behav Neurosci 115 5 (2001) 1145-1153
109. Monteggia L.M., et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 101 29 (2004) 10827-10832
110. Saarelainen T., et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 23 1 (2003) 349-357
111. Adachi M., et al. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 63 7 (2008) 642-649
112. Govindarajan A., et al. Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc Natl Acad Sci USA 103 35 (2006) 13208-13213
113. Koponen E., et al. Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines. Cell Mol Neurobiol 25 6 (2005) 973-980
114. Eisch A.J., et al. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biol Psychiatry 54 10 (2003) 994-1005
115. Berton O., et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311 5762 (2006) 864-868
116. Castren E., Voikar V., and Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 7 1 (2007) 18-21
117. Nestler E.J., and Carlezon Jr. W.A. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59 12 (2006) 1151-1159
118. Sairanen M., et al. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci 25 5 (2005) 1089-1094
119. Gass P., and Riva M.A. CREB, neurogenesis and depression. Bioessays 29 10 (2007) 957-961
120. Tiraboschi E., et al. Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades. Neuropsychopharmacology 29 10 (2004) 1831-1840
121. Wallace T.L., et al. Effects of cyclic adenosine monophosphate response element binding protein overexpression in the basolateral amygdala on behavioral models of depression and anxiety. Biol Psychiatry 56 3 (2004) 151-160
122. Dowlatshahi D., et al. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 352 9142 (1998) 1754-1755
123. Dwivedi Y., et al. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry 60 3 (2003) 273-282
124. Tsankova N.M., et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9 4 (2006) 519-525
125. Yamada M., and Higuchi T. Antidepressant-elicited changes in gene expression: remodeling of neuronal circuits as a new hypothesis for drug efficacy. Prog Neuropsychopharmacol Biol Psychiatry 29 6 (2005) 999-1009
126. Alfonso J., Frasch A.C., and Flugge G. Chronic stress, depression and antidepressants: effects on gene transcription in the hippocampus. Rev Neurosci 16 1 (2005) 43-56
127. Holmes P.V., Yoo H.S., and Dishman R.K. Voluntary exercise and clomipramine treatment elevate prepro-galanin mRNA levels in the locus coeruleus in rats. Neurosci Lett 408 1 (2006) 1-4
128. Iwata M., et al. Hippocampal synapsin I, growth-associated protein-43, and microtubule-associated protein-2 immunoreactivity in learned helplessness rats and antidepressant-treated rats. Neuroscience 141 3 (2006) 1301-1313
129. Sairanen M., et al. Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat. Neuroscience 144 1 (2007) 368-374
130. Thakker-Varia S., et al. Rab3A is required for brain-derived neurotrophic factor-induced synaptic plasticity: transcriptional analysis at the population and single-cell levels. J Neurosci 21 17 (2001) 6782-6790
131. Alder J., et al. Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J Neurosci 23 34 (2003) 10800-10808
132. Ring R.H., et al. Transcriptional profiling of brain-derived-neurotrophic factor-induced neuronal plasticity: a novel role for nociceptin in hippocampal neurite outgrowth. J Neurobiol 66 4 (2006) 361-377
133. Thakker-Varia S., et al. The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. J Neurosci 27 45 (2007) 12156-12167
134. Newton S.S., et al. Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci 23 34 (2003) 10841-10851
135. Altar C.A., et al. Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 24 11 (2004) 2667-2677
136. Ploski J.E., Newton S.S., and Duman R.S. Electroconvulsive seizure-induced gene expression profile of the hippocampus dentate gyrus granule cell layer. J Neurochem 99 4 (2006) 1122-1132
137. Conti B., et al. Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol Psychiatry 12 2 (2007) 167-189
138. Trani E., et al. Isolation and characterization of VGF peptides in rat brain. Role of PC1/3 and PC2 in the maturation of VGF precursor. J Neurochem 81 3 (2002) 565-574
139. Salton S.R., et al. VGF: a novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance. Front Neuroendocrinol 21 3 (2000) 199-219
140. Levi A., et al. Processing, distribution, and function of VGF, a neuronal and endocrine peptide precursor. Cell Mol Neurobiol 24 4 (2004) 517-533
141. Benson D.L., and Salton S.R. Expression and polarization of VGF in developing hippocampal neurons. Brain Res Dev Brain Res 96 1-2 (1996) 219-228
142. Laslop A., et al. Large dense-core vesicles in rat adrenal after reserpine: levels of mRNAs of soluble and membrane-bound constituents in chromaffin and ganglion cells indicate a biosynthesis of vesicles with higher secretory quanta. J Neurochem 62 6 (1994) 2448-2456
143. Possenti R., et al. Expression, processing, and secretion of the neuroendocrine VGF peptides by INS-1 cells. Endocrinology 140 8 (1999) 3727-3735
144. Hahm S., et al. Targeted deletion of the Vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance. Neuron 23 3 (1999) 537-548
145. Snyder S.E., and Salton S.R. Expression of VGF mRNA in the adult rat central nervous system. J Comp Neurol 394 1 (1998) 91-105
146. van den Pol A.N., et al. Hypothalamic expression of a novel gene product. VGF: immunocytochemical analysis. J Neurosci 9 12 (1989) 4122-4137
147. van den Pol A.N., et al. VGF expression in the brain. J Comp Neurol 347 3 (1994) 455-469
148. Bonni A., et al. Serine 133-phosphorylated CREB induces transcription via a cooperative mechanism that may confer specificity to neurotrophin signals. Mol Cell Neurosci 6 2 (1995) 168-183
149. Eagleson K.L., et al. Regional differences in neurotrophin availability regulate selective expression of VGF in the developing limbic cortex. J Neurosci 21 23 (2001) 9315-9324
150. D'Arcangelo G., et al. Activation of codependent transcription factors is required for transcriptional induction of the vgf gene by nerve growth factor and Ras. Mol Cell Biol 16 9 (1996) 4621-4631
151. Hahm S., et al. VGF is required for obesity induced by diet, gold thioglucose treatment, and agouti and is differentially regulated in pro-opiomelanocortin- and neuropeptide Y-containing arcuate neurons in response to fasting. J Neurosci 22 16 (2002) 6929-6938
152. Bartolomucci A., et al. TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. Proc Natl Acad Sci USA 103 39 (2006) 14584-14589
153. Bartolomucci A., et al. Chronic intracerebroventricular TLQP-21 delivery does not modulate the GH/IGF-1-axis and muscle strength in mice. Growth Horm IGF Res 17 4 (2007) 342-345
154. Succu S., et al. Pro-VGF-derived peptides induce penile erection in male rats: Involvement of paraventricular nitric oxide. Neuropharmacology 49 7 (2005) 1017-1025
155. Lombardo A., et al. A developmentally regulated nerve growth factor-induced gene, VGF, is expressed in geniculocortical afferents during synaptogenesis. Neuroscience 65 4 (1995) 997-1008
156. Snyder S.E., et al. The messenger RNA encoding VGF, a neuronal peptide precursor, is rapidly regulated in the rat central nervous system by neuronal activity, seizure and lesion. Neuroscience 82 1 (1998) 7-19
157. Mahata M., et al. Messenger RNA levels of chromogranin B, secretogranin II, and VGF in rat brain after AF64A-induced septohippocampal cholinergic lesions. J Neurochem 61 5 (1993) 1648-1656
158. Hevroni D., et al. Hippocampal plasticity involves extensive gene induction and multiple cellular mechanisms. J Mol Neurosci 10 2 (1998) 75-98
159. Sergeyev V., et al. Neuropeptide expression in rats exposed to chronic mild stresses. Psychopharmacology (Berl) 178 2-3 (2005) 115-124
160. Husum H., et al. Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 39 8 (2000) 1463-1473
161. Stogner K.A., and Holmes P.V. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur J Pharmacol 387 2 (2000) R9-10
162. Hunsberger J.G., et al. Antidepressant actions of the exercise-regulated gene VGF. Nat Med 13 12 (2007) 1476-1482
163. Malberg J.E., and Monteggia L.M. VGF a new player in antidepressant action?. Sci Signal 1 18 (2008) ppe19
164. Gomez-Pinilla F., Dao L., and So V. Physical exercise induces FGF-2 and its mRNA in the hippocampus. Brain Res 764 1-2 (1997) 1-8
165. Trejo J.L., Carro E., and Torres-Aleman I. Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J Neurosci 21 5 (2001) 1628-1634
166. Asano M., et al. Increase in serum vascular endothelial growth factor levels during altitude training. Acta Physiol Scand 162 4 (1998) 455-459
167. Yuan X., and Desiderio D.M. Human cerebrospinal fluid peptidomics. J Mass Spectrom 40 2 (2005) 176-181
168. Huang J.T., et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 3 11 (2006) pe428
169. Huang J.T., et al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS ONE 2 1 (2007) pe756
170. Pasinetti G.M., et al. Identification of potential CSF biomarkers in ALS. Neurology 66 8 (2006) 1218-1222
171. Ranganathan S., et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 95 5 (2005) 1461-1471
172. Ruetschi U., et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol 196 2 (2005) 273-281
173. Selle H., et al. Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease. Comb Chem High Throughput Screen 8 8 (2005) 801-806
174. Wedenoja J., et al. Replication of linkage on chromosome 7q22 and association of the regional Reelin gene with working memory in schizophrenia families. Mol Psychiatry 13 7 (2008) 673-684
175. Panksepp J., et al. Brain regional neuropeptide changes resulting from social defeat. Behav Neurosci 121 6 (2007) 1364-1371
176. Hebb A.L., et al. Intracerebroventricular D-Pen2.D-Pen5-enkephalin administration soon after stressor imposition influences behavioral responsivity to a subsequent stressor encounter in CD-1 mice. Pharmacol Biochem Behav 82 3 (2005) 453-469
177. Hebb A.L., et al. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Prog Neuropsychopharmacol Biol Psychiatry 29 8 (2005) 1225-1238
178. Kuteeva E., et al. Galanin, galanin receptor subtypes and depression-like behaviour. Cell Mol Life Sci 65 12 (2008) 1854-1863
179. Ogren S.O., et al. The neuropeptide galanin as an in vivo modulator of brain 5-HT1A receptors: possible relevance for affective disorders. Physiol Behav 92 1-2 (2007) 172-179
180. Guiard B.P., et al. Substance P neurokinin 1 receptor activation within the dorsal raphe nucleus controls serotonin release in the mouse frontal cortex. Mol Pharmacol 72 6 (2007) 1411-1418
181. Inui A. Neuropeptide Y feeding receptors: are multiple subtypes involved?. Trends Pharmacol Sci 20 2 (1999) 43-46
182. Vezzani A., Sperk G., and Colmers W.F. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci 22 1 (1999) 25-30
183. Redrobe J.P., et al. Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition. Brain Res 848 1-2 (1999) 153-166
184. Reibel S., et al. Overexpression of neuropeptide Y induced by brain-derived neurotrophic factor in the rat hippocampus is long lasting. Eur J Neurosci 12 2 (2000) 595-605
185. Obuchowicz E., Krysiak R., and Herman Z.S. Does neuropeptide Y (NPY) mediate the effects of psychotropic drugs?. Neurosci Biobehav Rev 28 6 (2004) 595-610
186. Baker R.A., Herkenham M., and Brady L.S. Effects of long-term treatment with antidepressant drugs on proopiomelanocortin and neuropeptide Y mRNA expression in the hypothalamic arcuate nucleus of rats. J Neuroendocrinol 8 5 (1996) 337-343
187. Caberlotto L., et al. Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. Brain Res Mol Brain Res 59 1 (1998) 58-65
188. Heilig M., et al. Antidepressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain. Eur J Pharmacol 147 3 (1988) 465-467
189. Zachrisson O., et al. Limbic effects of repeated electroconvulsive stimulation on neuropeptide Y and somatostatin mRNA expression in the rat brain. Brain Res Mol Brain Res 31 1-2 (1995) 71-85
190. Holmes P.V., et al. Effects of olfactory bulbectomy on neuropeptide gene expression in the rat olfactory/limbic system. Neuroscience 86 2 (1998) 587-596
191. Husum H., and Mathe A.A. Early life stress changes concentrations of neuropeptide Y and corticotropin-releasing hormone in adult rat brain. Lithium treatment modifies these changes. Neuropsychopharmacology 27 5 (2002) 756-764
192. Lim S., et al. Acupuncture increases neuropeptide Y expression in hippocampus of maternally-separated rats. Neurosci Lett 343 1 (2003) 49-52
193. Mathe A.A., et al. Neuropeptide Y, neurokinin A and neurotensin in brain regions of Fawn Hooded "depressed", Wistar, and Sprague Dawley rats. Effects of electroconvulsive stimuli. Prog Neuropsychopharmacol Biol Psychiatry 22 3 (1998) 529-546
194. Redrobe J.P., et al. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 26 5 (2002) 615-624
195. Ishida H., et al. Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor. Hippocampus 17 4 (2007) 271-280
196. Redrobe J.P., et al. Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test. Peptides 26 8 (2005) 1394-1400
197. Hashimoto H., et al. Plasma neuropeptide Y in patients with major depressive disorder. Neurosci Lett 216 1 (1996) 57-60
198. Gjerris A., et al. Cerebrospinal fluid concentrations of neuropeptide Y in depressed patients and in controls. J Psychiatry Neurosci 17 1 (1992) 23-27
199. Heilig M., et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 38 2 (2004) 113-121
200. Nikisch G., et al. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol 8 3 (2005) 403-410
201. Nilsson C., et al. Differences in the neuropeptide Y-like immunoreactivity of the plasma and platelets of human volunteers and depressed patients. Peptides 17 3 (1996) 359-362
202. Westrin A., Ekman R., and Traskman-Bendz L. Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt. Eur Neuropsychopharmacol 9 3 (1999) 205-211
203. Widerlov E., et al. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 22 1 (1988) 69-79
204. Mathe A.A. Neuropeptides and electroconvulsive treatment. J Ect 15 1 (1999) 60-75
205. Caberlotto L., and Hurd Y.L. Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder. Neuroreport 10 8 (1999) 1747-1750
206. Kuteeva E., et al. Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level. Neuropsychopharmacology 33 11 (2008) 2573-2585
207. Lu X., et al. Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. Neuropeptides (2008)
208. McLean S. Do substance P and the NK1 receptor have a role in depression and anxiety?. Curr Pharm Des 11 12 (2005) 1529-1547
209. Gavioli E.C., and Calo G. Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands. Naunyn Schmiedebergs Arch Pharmacol 372 5 (2006) 319-330
210. Scott L.V., and Dinan T.G. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci 62 22 (1998) 1985-1998
211. Uvnas-Moberg K. Oxytocin linked antistress effects-the relaxation and growth response. Acta Physiol Scand Suppl 640 (1997) 38-42
212. Ring R.H. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr Pharm Des 11 2 (2005) 205-225
213. Scantamburlo G., et al. Neurohypophyseal neuropeptides and unipolar depression: which future?. Rev Med Liege 63 5-6 (2008) 385-390
214. Simon N.G., et al. Vasopressin antagonists as anxiolytics and antidepressants: recent developments. Recent Patents CNS Drug Discov 3 2 (2008) 77-93
215. Ring R.H., et al. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology (Berl) 185 2 (2006) 218-225
216. Grote H.E., and Hannan A.J. Regulators of adult neurogenesis in the healthy and diseased brain. Clin Exp Pharmacol Physiol 34 5-6 (2007) 533-545
217. Manganas L.N., et al. Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain. Science 318 5852 (2007) 980-985
218. Sheline Y.I., et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 93 9 (1996) 3908-3913
219. Gould E., et al. Adrenal hormones suppress cell division in the adult rat dentate gyrus. J Neurosci 12 9 (1992) 3642-3650
220. Tanapat P., Galea L.A., and Gould E. Stress inhibits the proliferation of granule cell precursors in the developing dentate gyrus. Int J Dev Neurosci 16 3-4 (1998) 235-239
221. Czeh B., et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA 98 22 (2001) 12796-12801
222. Malberg J.E., and Duman R.S. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology 28 9 (2003) 1562-1571
223. Pham K., et al. Repeated restraint stress suppresses neurogenesis and induces biphasic PSA-NCAM expression in the adult rat dentate gyrus. Eur J Neurosci 17 4 (2003) 879-886
224. Airan R.D., et al. High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science 317 5839 (2007) 819-823
225. Santarelli L., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 5634 (2003) 805-809
226. Vollmayr B., et al. Reduced cell proliferation in the dentate gyrus is not correlated with the development of learned helplessness. Biol Psychiatry 54 10 (2003) 1035-1040
227. Czeh B., et al. Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology 32 7 (2007) 1490-1503
228. Sahay A., and Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci 10 9 (2007) 1110-1115
229. Malberg J.E., et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20 24 (2000) 9104-9110
230. Namestkova K., Simonova Z., and Sykova E. Decreased proliferation in the adult rat hippocampus after exposure to the Morris water maze and its reversal by fluoxetine. Behav Brain Res 163 1 (2005) 26-32
231. Encinas J.M., Vaahtokari A., and Enikolopov G. Fluoxetine targets early progenitor cells in the adult brain. Proc Natl Acad Sci USA 103 21 (2006) 8233-8238
232. Nakagawa S., et al. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J Neurosci 22 9 (2002) 3673-3682
233. Scharfman H., et al. Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Exp Neurol 192 2 (2005) 348-356
234. Perera T.D., et al. Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci 27 18 (2007) 4894-4901
235. Sheline Y.I., Gado M.H., and Kraemer H.C. Untreated depression and hippocampal volume loss. Am J Psychiatry 160 8 (2003) 1516-1518
236. Vermetten E., et al. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry 54 7 (2003) 693-702
237. Jiang W., et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 115 11 (2005) 3104-3116
238. Holick K.A., et al. Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 33 2 (2008) 406-417
239. Bjarkam C.R., Sorensen J.C., and Geneser F.A. Distribution and morphology of serotonin-immunoreactive axons in the hippocampal region of the New Zealand white rabbit. I. Area dentata and hippocampus. Hippocampus 13 1 (2003) 21-37
240. Bannerman D.M., et al. Regional dissociations within the hippocampus-memory and anxiety. Neurosci Biobehav Rev 28 3 (2004) 273-283
241. Manji H.K., et al. The underlying neurobiology of bipolar disorder. World Psychiatry 2 3 (2003) 136-146
242. Chen A.C., et al. Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry 49 9 (2001) 753-762
243. Gur T.L., et al. cAMP response element-binding protein deficiency allows for increased neurogenesis and a rapid onset of antidepressant response. J Neurosci 27 29 (2007) 7860-7868
244. Benraiss A., et al. Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain. J Neurosci 21 17 (2001) 6718-6731
245. Pencea V., et al. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci 21 17 (2001) 6706-6717
246. Rossi C., et al. Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment. Eur J Neurosci 24 7 (2006) 1850-1856
247. Lee J., Seroogy K.B., and Mattson M.P. Dietary restriction enhances neurotrophin expression and neurogenesis in the hippocampus of adult mice. J Neurochem 80 3 (2002) 539-547
248. Bath K.G., et al. Variant brain-derived neurotrophic factor (Val66Met) alters adult olfactory bulb neurogenesis and spontaneous olfactory discrimination. J Neurosci 28 10 (2008) 2383-2393
249. Lee R., et al. Regulation of cell survival by secreted proneurotrophins. Science 294 5548 (2001) 1945-1948
250. Lu B., Pang P.T., and Woo N.H. The yin and yang of neurotrophin action. Nat Rev Neurosci 6 8 (2005) 603-614
251. Li Y., et al. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 59 3 (2008) 399-412
252. Banasr M., and Duman R.S. Keeping 'trk' of antidepressant actions. Neuron 59 3 (2008) 349-351
253. van Praag H., et al. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc Natl Acad Sci USA 96 23 (1999) 13427-13431
254. Fabel K., et al. VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur J Neurosci 18 10 (2003) 2803-2812
255. van Praag H., et al. Functional neurogenesis in the adult hippocampus. Nature 415 6875 (2002) 1030-1034
256. Meshi D., et al. Hippocampal neurogenesis is not required for behavioral effects of environmental enrichment. Nat Neurosci 9 6 (2006) 729-731
257. Severini C., et al. TLQP-21, a neuroendocrine VGF-derived peptide, prevents cerebellar granule cells death induced by serum and potassium deprivation. J Neurochem 104 2 (2008) 534-544
258. Howell O.W., et al. Neuropeptide Y is neuroproliferative for post-natal hippocampal precursor cells. J Neurochem 86 3 (2003) 646-659
259. Howell O.W., et al. Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J Neurochem 93 3 (2005) 560-570
260. Persson A.I., et al. Differential regulation of hippocampal progenitor proliferation by opioid receptor antagonists in running and non-running spontaneously hypertensive rats. Eur J Neurosci 19 7 (2004) 1847-1855
261. Koehl M., et al. Exercise-induced promotion of hippocampal cell proliferation requires beta-endorphin. FASEB J 22 7 (2008) 2253-2262
262. Stanic D., et al. Peptidergic influences on proliferation, migration, and placement of neural progenitors in the adult mouse forebrain. Proc Natl Acad Sci USA 105 9 (2008) 3610-3615
263. Park S.W., et al. Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions. J Neurosurg 107 3 (2007) 593-599
264. Morcuende S., et al. Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice. Eur J Neurosci 18 7 (2003) 1828-1836
265. Mazarati A., et al. Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur J Neurosci 19 12 (2004) 3235-3244
266. Surget A., et al. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry 64 4 (2008) 293-301
267. Cameron H.A., McEwen B.S., and Gould E. Regulation of adult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus. J Neurosci 15 6 (1995) 4687-4692
268. Deisseroth K., et al. Excitation-neurogenesis coupling in adult neural stem/progenitor cells. Neuron 42 4 (2004) 535-552
269. Ge S., et al. GABA regulates synaptic integration of newly generated neurons in the adult brain. Nature 439 7076 (2006) 589-593
270. Tashiro A., et al. NMDA-receptor-mediated, cell-specific integration of new neurons in adult dentate gyrus. Nature 442 7105 (2006) 929-933
271. Toni N., et al. Neurons born in the adult dentate gyrus form functional synapses with target cells. Nat Neurosci 11 8 (2008) 901-907
272. Duman R.S., et al. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 48 8 (2000) 732-739
273. Mayberg H.S. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 9 3 (1997) 471-481
274. Bremner J.D., et al. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 54 4 (1997) 364-374
275. Drevets W.C. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11 2 (2001) 240-249
276. Lee A.L., Ogle W.O., and Sapolsky R.M. Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord 4 2 (2002) 117-128
277. Nestler E.J., et al. Neurobiology of depression. Neuron 34 1 (2002) 13-25
278. Mowla A., Mosavinasab M., and Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 27 1 (2007) 67-70
279. Pittenger C., Sanacora G., and Krystal J.H. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 6 2 (2007) 101-115
280. Zarate Jr. C.A., et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 1003 (2003) 273-291
281. Bleakman D., Alt A., and Witkin J.M. AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets 6 2 (2007) 117-126
282. Duman R.S., and Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59 12 (2006) 1116-1127
283. Carlezon Jr. W.A., Duman R.S., and Nestler E.J. The many faces of CREB. Trends Neurosci 28 8 (2005) 436-445
284. Larsen M.H., et al. Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine. Eur J Pharmacol 555 2-3 (2007) 115-121
285. Alme M.N., et al. Chronic fluoxetine treatment induces brain region-specific upregulation of genes associated with BDNF-induced long-term potentiation. Neural Plast 2007 (2007) p26496
286. Shors T.J., et al. Inescapable versus escapable shock modulates long-term potentiation in the rat hippocampus. Science 244 4901 (1989) 224-226
287. Holderbach R., et al. Enhanced long-term synaptic depression in an animal model of depression. Biol Psychiatry 62 1 (2007) 92-100
288. Stewart C.A., and Reid I.C. Repeated ECS and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity. Psychopharmacology (Berl) 148 3 (2000) 217-223
289. Levkovitz Y., and Segal M. Aging affects transcranial magnetic modulation of hippocampal evoked potentials. Neurobiol Aging 22 2 (2001) 255-263
290. Vouimba R.M., Munoz C., and Diamond D.M. Differential effects of predator stress and the antidepressant tianeptine on physiological plasticity in the hippocampus and basolateral amygdala. Stress 9 1 (2006) 29-40
291. Kobayashi K., et al. Chronic fluoxetine bidirectionally modulates potentiating effects of serotonin on the hippocampal mossy fiber synaptic transmission. J Neurosci 28 24 (2008) 6272-6280
292. Maya Vetencourt J.F., et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 320 5874 (2008) 385-388
293. Farmer J., et al. Effects of voluntary exercise on synaptic plasticity and gene expression in the dentate gyrus of adult male Sprague-Dawley rats in vivo. Neuroscience 124 1 (2004) 71-79
294. Vaynman S., Ying Z., and Gomez-Pinilla F. Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur J Neurosci 20 10 (2004) 2580-2590
295. Brouillette J., et al. Hippocampal gene expression profiling reveals the possible involvement of Homer1 and GABA(B) receptors in scopolamine-induced amnesia. J Neurochem 102 6 (2007) 1978-1989
296. Sugaya K., et al. Septo-hippocampal cholinergic and neurotrophin markers in age-induced cognitive decline. Neurobiol Aging 19 4 (1998) 351-361
297. Kranenburg O., et al. Amyloid-beta-stimulated plasminogen activation by tissue-type plasminogen activator results in processing of neuroendocrine factors. Neuroscience 131 4 (2005) 877-886
298. Bozdagi O., Huntley G.W., and Salton S.R. Role of VGF peptide in hippocampal synaptic function. Soc Neurosci Meeting 760 (2007) 9
299. Whittaker E., Vereker E., Lynch M.A., and Neuropeptide. Y inhibits glutamate release and long-term potentiation in rat dentate gyrus. Brain Res 827 1-2 (1999) 229-233
300. Flood J.F., et al. Modulation of memory processing by neuropeptide Y varies with brain injection site. Brain Res 503 1 (1989) 73-82
301. Flood J.F., and Morley J.E. Dissociation of the effects of neuropeptide Y on feeding and memory: evidence for pre- and postsynaptic mediation. Peptides 10 5 (1989) 963-966
302. Redrobe J.P., et al. Characterization of neuropeptide Y, Y(2) receptor knockout mice in two animal models of learning and memory processing. J Mol Neurosci 22 3 (2004) 159-166
303. Haddjeri N., and Blier P. Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biol Psychiatry 50 3 (2001) 191-199
304. Stacey A.E., Woodhall G.L., and Jones R.S. Neurokinin-receptor-mediated depolarization of cortical neurons elicits an increase in glutamate release at excitatory synapses. Eur J Neurosci 16 10 (2002) 1896-1906
305. Stacey A.E., Woodhall G.L., and Jones R.S. Activation of neurokinin-1 receptors promotes GABA release at synapses in the rat entorhinal cortex. Neuroscience 115 2 (2002) 575-586
306. Neu A., Foldy C., and Soltesz I. Postsynaptic origin of CB1-dependent tonic inhibition of GABA release at cholecystokinin-positive basket cell to pyramidal cell synapses in the CA1 region of the rat hippocampus. J Physiol 578 Pt 1 (2007) 233-247
307. Karson M.A., Whittington K.C., and Alger B.E. Cholecystokinin inhibits endocannabinoid-sensitive hippocampal IPSPs and stimulates others. Neuropharmacology 54 1 (2008) 117-128
308. McQuiston A.R. Layer selective presynaptic modulation of excitatory inputs to hippocampal cornu Ammon 1 by mu-opioid receptor activation. Neuroscience 151 1 (2008) 209-221
309. Kehr J., et al. Galanin is a potent in vivo modulator of mesencephalic serotonergic neurotransmission. Neuropsychopharmacology 27 3 (2002) 341-356
310. Kokaia M., et al. Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin. Proc Natl Acad Sci USA 98 24 (2001) 14006-14011
311. Dubrovsky B., et al. Oxytocin induces long-term depression on the rat dentate gyrus: possible ATPase and ectoprotein kinase mediation. Brain Res Bull 58 2 (2002) 141-147
312. Noda Y., et al. Role of nociceptin systems in learning and memory. Peptides 21 7 (2000) 1063-1069
313. Wei W.Z., and Xie C.W. Orphanin FQ suppresses NMDA receptor-dependent long-term depression and depotentiation in hippocampal dentate gyrus. Learn Mem 6 5 (1999) 467-477
314. Manabe T., et al. Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. Nature 394 6693 (1998) 577-581
315. Bongsebandhu-phubhakdi S., and Manabe T. The neuropeptide nociceptin is a synaptically released endogenous inhibitor of hippocampal long-term potentiation. J Neurosci 27 18 (2007) 4850-4858
316. Sandin J., Ogren S.O., and Terenius L. Nociceptin/orphanin FQ modulates spatial learning via ORL-1 receptors in the dorsal hippocampus of the rat. Brain Res 997 2 (2004) 222-233
317. Tian J.H., et al. Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br J Pharmacol 120 4 (1997) 676-680
318. Xu X.J., Hao J.X., and Wiesenfeld-Hallin Z. Nociceptin or antinociceptin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat. Neuroreport 7 13 (1996) 2092-2094
319. Okuda-Ashitaka E., et al. Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature 392 6673 (1998) 286-289
320. Toni N., et al. Synapse formation on neurons born in the adult hippocampus. Nat Neurosci 10 6 (2007) 727-734
321. Tashiro A., Makino H., and Gage F.H. Experience-specific functional modification of the dentate gyrus through adult neurogenesis: a critical period during an immature stage. J Neurosci 27 12 (2007) 3252-3259
322. Witkin J.M., et al. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord Drug Targets 6 2 (2007) 87-100
323. Wang J.W., et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci 28 6 (2008) 1374-1384
324. McEwen B.S., and Magarinos A.M. Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders. Hum Psychopharmacol 16 S1 (2001) S7-S19
325. Duman R.S., Malberg J., and Nakagawa S. Regulation of adult neurogenesis by psychotropic drugs and stress. J Pharmacol Exp Ther 299 2 (2001) 401-407
326. Watanabe Y., et al. Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol 222 1 (1992) 157-162
327. Magarinos A.M., Deslandes A., and McEwen B.S. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol 371 2-3 (1999) 113-122
328. Vaidya V.A., et al. Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures. Neuroscience 89 1 (1999) 157-166
329. Madhav T.R., et al. Repeated electroconvulsive shock promotes the sprouting of serotonergic axons in the lesioned rat hippocampus. Neuroscience 97 4 (2000) 677-683
330. Lamont S.R., Paulls A., and Stewart C.A. Repeated electroconvulsive stimulation, but not antidepressant drugs, induces mossy fibre sprouting in the rat hippocampus. Brain Res 893 1-2 (2001) 53-58
331. Coyle J.T., and Duman R.S. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38 2 (2003) 157-160
332. Vaidya V.A., and Duman R.S. Depresssion-emerging insights from neurobiology. Br Med Bull 57 (2001) 61-79
333. Mamounas L.A., et al. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 15 12 (1995) 7929-7939
334. Mamounas L.A., et al. BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain. J Neurosci 20 2 (2000) 771-782
335. Patel M.N., and McNamara J.O. Selective enhancement of axonal branching of cultured dentate gyrus neurons by neurotrophic factors. Neuroscience 69 3 (1995) 763-770
336. Labelle C., Leclerc N., and Exogenous B.D.N.F. NT-3, NT-4 differentially regulate neurite outgrowth in cultured hippocampal neurons. Brain Res Dev Brain Res 123 1 (2000) 1-11
337. Cohen-Cory S. The developing synapse: construction and modulation of synaptic structures and circuits. Science 298 5594 (2002) 770-776
338. Tyler W.J., and Pozzo-Miller L. Miniature synaptic transmission and BDNF modulate dendritic spine growth and form in rat CA1 neurones. J Physiol 553 Pt 2 (2003) 497-509
339. - co-transporter KCC2. Development 130 7 (2003) 1267-1280
340. Genoud C., et al. Altered synapse formation in the adult somatosensory cortex of brain-derived neurotrophic factor heterozygote mice. J Neurosci 24 10 (2004) 2394-2400
341. Lieske V., Bennett-Clarke C.A., and Rhoades R.W. Effects of serotonin on neurite outgrowth from thalamic neurons in vitro. Neuroscience 90 3 (1999) 967-974
342. Kvachnina E., et al. 5-HT7 receptor is coupled to Galpha subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology. J Neurosci 25 34 (2005) 7821-7830
343. Fricker A.D., et al. Serotonin receptor activation leads to neurite outgrowth and neuronal survival. Brain Res Mol Brain Res 138 2 (2005) 228-235
344. Mazer C., et al. Serotonin depletion during synaptogenesis leads to decreased synaptic density and learning deficits in the adult rat: a possible model of neurodevelopmental disorders with cognitive deficits. Brain Res 760 1-2 (1997) 68-73